ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $103.4286.

A number of equities analysts have weighed in on the company. Barclays started coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $81.27 on Friday. The company has a fifty day moving average price of $81.75 and a 200 day moving average price of $85.37. The firm has a market cap of $1.83 billion, a PE ratio of 49.86 and a beta of 0.50. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals has a 1-year low of $54.10 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts predict that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the transaction, the vice president owned 74,374 shares of the company’s stock, valued at $6,271,959.42. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Chad Gassert sold 14,642 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the transaction, the senior vice president owned 158,584 shares in the company, valued at $14,125,076.88. This represents a 8.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 28,101 shares of company stock worth $2,453,063. Corporate insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. lifted its holdings in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 510 shares during the period. Newbridge Financial Services Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of ANI Pharmaceuticals in the second quarter valued at about $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.